Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MB CART20.1

Next Previous
Drug Profile

MB CART20.1

Alternative Names: Anti-CD20 CAR T cells - Miltenyi Biotec; CD20-targeting CAR T Cells - Miltenyi Biotec; MB-CART20.1

Latest Information Update: 05 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Miltenyi Biotec GmbH
  • Developer German Aerospace Center; Miltenyi Biotec GmbH
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma
  • Clinical Phase Unknown Malignant melanoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 17 Sep 2024 Miltenyi Biomedicine GmbH completes a phase I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Germany (IV) (NCT03664635)
  • 05 May 2024 Clinical trials in Malignant melanoma (In adults, In children, In adolescents, In the elderly, Second-line therapy or greater) in Germany (IV)
  • 05 May 2024 Clinical trials in Non-Hodgkin's lymphoma (In adults, In children, In adolescents, In the elderly, Second-line therapy or greater) in Germany (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top